BioStem Technologies, Inc. (BSEM) Form 8-K — Aug 12, 2026
BioStem Technologies (Nasdaq: BSEM) reported second quarter 2026 net revenue of $7.9 million, up 29% sequentially from $6.1 million but down from $11.0 million in the year-ago quarter, and raised full-year 2026 revenue guidance to a range of $26 million to $29 million from the prior $25 million to $29 million. Q2 revenue was primarily driven by Neox and Clarix product sales, with hospital revenue of $6.7 million and physician office revenue of $1.1 million. The company swung to a GAAP net loss of $9.0 million, or $0.52 per share, versus net income of $10,613 in Q2 2025, and posted an Adjusted EBITDA loss of $4.6 million.
Key figures
- Revenue
- 7899249
- Guidance
- FY2026 revenue of $26 million to $29 million, raised from prior guidance of $25 million to $29 million
- Total Debt
- 1000000
- Revenue Yoy
- -27.9% (derived from stated figures: $7,899,249 vs $10,963,174 in Q2 2025)
- Total Assets
- 48818296
- Cash Position
- 6962492
- Shares Outstanding
- 17839467
- Debt resolved
- $5.3 million resolved via $3.5 million cash payment and $1.0 million promissory note
- Q2 2025 revenue
- 10963174
- Private placement
- $2.5 million with first institutional investor
- Total liabilities
- 21203699
- New design patents
- 8
- Accumulated deficit
- 38965381
- Cash end of q1 2026
- $13.7 million
- Gross margin q2 2025
- 94%
- Gross margin q2 2026
- 61%
- Gross profit q2 2026
- 4840661
- Nasdaq uplisting date
- August 7, 2026
- Adjusted ebitda q2 2025
- 2509538
- Hospital revenue q2 2026
- $6.7 million
- Sequential revenue growth
- 29% from $6.1 million in Q1 2026
- Operating expenses q2 2026
- 13241348
- Cash used in operations q2 2026
- $5.5 million
- Contingent consideration payable
- 10000000
- Physician office revenue q2 2026
- $1.1 million
Price after filing
Close on the filing date to close N calendar days later (from $3.80). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.